-
Media Release
Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program
-
Media Release
Novartis commits to addressing racial disparities in breast cancer screening, treatment and care
-
Media Release
Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media Release
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
-
Media Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media Release
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
-
Media Release
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media Release
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender